BNTX BioNTech SE
Company Analysis
Latest News
BioNTech's second quarter revenue fell 60% to €105.6 million, driving a wider net loss
BioNTech reported second quarter revenue of €105.6 million, a sharp decrease from €260.8 million in the prior-year period, primarily due to declining COVID-19...
BioNTech's second quarter revenue fell to €105.6 million on lower vaccine demand, prompting a cut to its full-year 2026 guidance.
BioNTech reported second quarter revenues of €105.6 million, a significant decline from the prior year, driven by lower demand for its COVID-19 vaccine. The...
BioNTech SE Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
BioNTech is expected to report a Q2 2026 revenue of approximately $185.4 million and a consensus EPS of -$2.58, as the stock trades near $94.12 against a...
BioNTech and Pfizer Secure EU Approval for 2026-2027 COVID-19 Vaccine
The European Commission authorized BioNTech and Pfizer’s updated COVID-19 vaccine for the 2026-2027 season. This marketing authorization covers individuals...
🔴 BioNTech is trading 4.6% down today on macro uncertainty following new U.S. tariffs
BioNTech is trading 4.6% down at $85.22 in thin pre-market action, as the stock faces pressure from broader macro uncertainty following new U.S. tariffs on...
🔴 BioNTech is trading 4.4% down today with no clear company-specific catalyst
BioNTech is trading at $88.13 (-4.37%) in after-hours trading following an isolated selloff with no clear company-specific catalyst. • The decline follows a...
Sanofi Files New Patent Lawsuits Against Pfizer and BioNTech Over COVID-19 Vaccine Technology
Sanofi initiated new patent infringement lawsuits against Pfizer and its partner BioNTech, as well as Moderna. The lawsuits concern technology used in their...
🟢 BioNTech is trading 7% up today with no clear catalyst identified yet
BioNTech is trading at $96.51 (+7%) in after-hours trading with no clear catalyst identified yet, as the move likely reflects opportunistic buying following...
ARK Invest Sells $7.4 Million BioNTech Stake, Funds SpaceX
Cathie Wood’s ARK Invest sold 78,211 shares of BioNTech on July 8, 2026. The transaction was valued at approximately $7.4 million. ARK Invest reported the...
BioNTech Defeats mRNA Patent Claim, Court Rules Rival Patent Invalid
BioNTech and Pfizer secured a legal victory at the Unified Patent Court (UPC) in Munich. The court dismissed an infringement claim brought by Promosome...
BioNTech SE Q1 2026 Earnings Preview: What Analysts Expect on May 11, 2026
For the first quarter of 2026, analysts expect BioNTech to report a consensus revenue of approximately $207.42 million and an EPS loss of $2.03. With the stock...
BioNTech SE Q1 2026 Earnings Preview: What Analysts Expect on May 05, 2026
Consensus revenue is $220.02 million with an expected loss of $2.52 per share, as the current $97.54 stock price remains well below the $133.13 analyst...
BioNTech SE Q4 2025 Earnings Preview: What Analysts Expect on March 10, 2026
BioNTech SE is expected to report Q4 2025 revenue of approximately €816.04 million and a loss per share of $0.47, with its current $101.50 stock price trading...